Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.

Álvaro Díaz-González Víctor SapenaLoreto BoixMercè BrunetFerràn TorresNeus LLarchEsther SamperOlga MillánJosep CorominasGemma IserteMarco Sanduzzi-Zamparelli Leonardo Gomes da FonsecaAnna DarnellErnest BelmonteAlejandro FornerCarmen AyusoJordi Bruix Maria Reig

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

Sorafenib's pharmacokinetics is heterogeneous across HCC patients. This heterogeneity affects adverse events development and must be taken into account in setting the dose and timing of its combination with checkpoint inhibitors.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
dna damage
prognostic factors
cell proliferation
patient reported